BR0005322A - Amidas do ácido 7-[(4'-trifluorometil-bifenil-2-carbonil) amino]-quinolina-3-carboxìlico e métodos de inibição da secreção de apolipoproteìna b - Google Patents

Amidas do ácido 7-[(4'-trifluorometil-bifenil-2-carbonil) amino]-quinolina-3-carboxìlico e métodos de inibição da secreção de apolipoproteìna b

Info

Publication number
BR0005322A
BR0005322A BR0005322-8A BR0005322A BR0005322A BR 0005322 A BR0005322 A BR 0005322A BR 0005322 A BR0005322 A BR 0005322A BR 0005322 A BR0005322 A BR 0005322A
Authority
BR
Brazil
Prior art keywords
apolipoprotein
methods
secretion
biphenyl
trifluoromethyl
Prior art date
Application number
BR0005322-8A
Other languages
English (en)
Inventor
Peter Bertinato
Ernest Seiichi Hamanaka
Roger Benjamin Ruggeri
Douglas Paul Wilson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0005322A publication Critical patent/BR0005322A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

Patente de Invenção: <B>"AMIDAS DO áCIDO 7-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)AMINO]-QUINOLI NA-3-CARBOXìLICO E MéTODOS DE INIBIçãO DA SECREçãO DE APOLIPOPROTEìNA B"<D>. A invenção diz respeito a compostos de Fórmula I que inibem a secreção de apolipoproteína B, a composições farmacêuticas que compreendem os compostos e a métodos de tratamento e/ou prevenção de aterosclerose, obesidade, diabetes, hiperlipdemia, hiperlipoproteinemia, hipercolesterolemia, hipertrigliceridemia, hipoalfalipoproteinemia, pancreatite, enfarte do miocárdio, derrame cerebral, restenose ou Síndrome X. Esta invenção também refere-se a métodos de redução da secreção de apolipoproteína B e/ou inibição da proteína de transferência de triglicerídeo microssómico.
BR0005322-8A 1999-11-10 2000-11-09 Amidas do ácido 7-[(4'-trifluorometil-bifenil-2-carbonil) amino]-quinolina-3-carboxìlico e métodos de inibição da secreção de apolipoproteìna b BR0005322A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16480399P 1999-11-10 1999-11-10
US22495600P 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
BR0005322A true BR0005322A (pt) 2001-07-17

Family

ID=26860863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0005322-8A BR0005322A (pt) 1999-11-10 2000-11-09 Amidas do ácido 7-[(4'-trifluorometil-bifenil-2-carbonil) amino]-quinolina-3-carboxìlico e métodos de inibição da secreção de apolipoproteìna b

Country Status (6)

Country Link
US (2) US6369075B1 (pt)
EP (1) EP1099701A1 (pt)
JP (1) JP3524868B2 (pt)
BR (1) BR0005322A (pt)
CA (1) CA2325358C (pt)
MX (1) MXPA00011105A (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6889385B1 (en) * 2000-01-14 2005-05-03 Terayon Communication Systems, Inc Home network for receiving video-on-demand and other requested programs and services
US20020059637A1 (en) * 2000-01-14 2002-05-16 Rakib Selim Shlomo Home gateway for video and data distribution from various types of headend facilities and including digital video recording functions
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE10033337A1 (de) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
EE05452B1 (et) * 2001-06-28 2011-08-15 Pfizer Products Inc. Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid
HUP0700124A2 (en) * 2001-10-25 2007-06-28 Takeda Chemical Industries Ltd Quinoline compound
AU2003205570A1 (en) * 2002-01-10 2003-07-24 Boehringer Ingelheim Pharma Gmbh And Co. Kg Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
EP2033953A1 (en) * 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
AU2003248354A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Acc inhibitors
CN101838218A (zh) 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
AU2003262947A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
WO2004019933A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
JP2006516028A (ja) * 2002-12-20 2006-06-15 ファイザー・プロダクツ・インク ミクロソームトリグリセリド輸送タンパク質阻害剤
CA2505604A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US7705016B2 (en) * 2003-02-13 2010-04-27 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
CA2513092C (en) * 2003-02-13 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2004248302B2 (en) 2003-06-19 2009-07-30 Merck Serono Sa Use of prion conversion modulating agents
PL1651232T3 (pl) * 2003-07-23 2011-05-31 Synta Pharmaceuticals Corp Związki do zastosowań związanych z zapaleniami i odpornością
CA2530352A1 (en) 2003-07-24 2005-02-03 Astellas Pharma Inc. Quinolone derivative or salt thereof
JP4832897B2 (ja) * 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
GB0323348D0 (en) * 2003-10-06 2003-11-05 Cambridge Theranostics Ltd Methods and means for modulating lipid metabolism
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
JP2007525482A (ja) * 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
AU2005214159A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
WO2005086904A2 (en) * 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
EP1843819A2 (en) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
JP5390404B2 (ja) * 2007-02-16 2014-01-15 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための環状部分を有する化合物及び組成物
PT2225261E (pt) 2007-12-03 2016-06-09 Obe Therapy Biotechnology Inibidores boropeptídicos de enteropeptidase e suas utilizações no tratamento de obesidade, excesso de peso e/ou doenças associadas com um metabolismo anormal da gordura
US8373007B2 (en) 2008-03-28 2013-02-12 Takeda Pharmaceutical Company Ltd. Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
WO2013036676A1 (en) 2011-09-06 2013-03-14 New York Blood Center, Inc. Hiv inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
ES2764440T3 (es) 2014-09-19 2020-06-03 New York Blood Center Inc Fenilpirrolcarboxamidas sustituidas con actividad terapéutica en VIH
GB2589910B (en) 2019-12-12 2021-12-01 Henkel IP & Holding GmbH Process for preparing cyanoacetates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529849T2 (de) * 1995-06-07 2003-09-04 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
CN1209803A (zh) 1996-01-16 1999-03-03 布里斯托尔-迈尔斯斯奎布公司 微粒体甘油三酯转移蛋白的构象限制性芳族抑制剂及方法
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
US20020132806A1 (en) 2002-09-19
MXPA00011105A (es) 2002-05-23
US6713489B2 (en) 2004-03-30
US6369075B1 (en) 2002-04-09
JP3524868B2 (ja) 2004-05-10
EP1099701A1 (en) 2001-05-16
CA2325358C (en) 2005-08-02
JP2001139555A (ja) 2001-05-22
CA2325358A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
BR0005322A (pt) Amidas do ácido 7-[(4&#39;-trifluorometil-bifenil-2-carbonil) amino]-quinolina-3-carboxìlico e métodos de inibição da secreção de apolipoproteìna b
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
YU20302A (sh) Upotreba retigabina u lečenju neuropatskog bola
BR9714364A (pt) Amidas inibidoras da secreção de apo b/mtp
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
BR9813264A (pt) ácidos graxos, sistemas tensoativos e produtos de consumo baseados nos mesmos
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
BR9909730A (pt) Dihidropirimidinas
BR0212226A (pt) Pirrolo pirimidinas como agentes para inibição de cisteìna proteases
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
BR9802851A (pt) Antibióticos de macrolìdeo substituìdos por c-4
IL160769A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
UY26851A1 (es) Derivados de la 4-fenilpiridina
ATE465757T1 (de) Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
EA200001114A3 (ru) 2-(3,5-БИСТРИФТОРОМЕТИЛФЕНИЛ)-N-МЕТИЛ-N-(6-МОРФОЛИН-4-ИЛ-4-о-ТОЛИЛПИРИДИН-3-ИЛ)ИЗОБУТИРАМИД
BR0212899A (pt) Compostos orgânicos
BR0011122A (pt) Antagonistas de receptor il-8
BR9916485A (pt) Combinações de inibidores da proteìna de transferência do éster colesterìlico e derivados do ácido fìbrico em indicações cardiovasculares
AU4568400A (en) Sphingomyelinase inhibitor
PT1161239E (pt) 3-ciclopropilmetoxi-4-difluorometoxi-n-(3,5-dicloropirid-4-il)-benzamida para o tratamento da esclerose multipla
BR0116263A (pt) Derivados de diidroindol e tetraidroquinolina
BR0113814A (pt) Amidas de ácido fenilciclohexanocarboxìlico e sua aplicação
NO20033634D0 (no) GLYT-1 inhibitorer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A A 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2135 DE 06/12/2011.